PAHO: Omicron to become dominant variant in Americas shortly | Health and Fitness

MIAMI (AP) — The Pan American Health Organization said Wednesday it expects omicron to become the predominant coronavirus variant in the Americas in the coming weeks, where confirmed cases have reached record levels.

The health agency added that although healthcare systems face challenges with rising hospitalizations, vaccination has meant that COVID-19 deaths have not increased at the same rate as infections.

“While delta is still causing new infections in the Americas, based on current trends, omicron is on track to become the dominant strain in our region,” Carissa Etienne, director of the agency known by its initials PAHO, said during an online news conference.

PAHO said coronavirus virus infections across the Americas almost doubled to 6.1 million on Jan. 8, from 3.4 million cases on Jan. 1. The number of cases was 250% higher than a year earlier, when there were 2.4 million.

It said that in the first week of 2022, deaths related to COVID-19 in the Americas increased 31% from the previous week.

The omicron variant, which spreads more easily, has been detected in 42 of the 56 countries and territories of the Americas.

The United States is reporting the highest number of cases, while Canada is also registering a rebound. In the Caribbean, Puerto Rico and the Dominican Republic have seen the highest increases, while Belize and Panama have seen rises in Central America.

Read More... Read More

‘Game changer’ Covid capsule might be obtainable in US shortly, but its results will hinge on rapid testing

Now under federal overview, both pills are being hailed by infectious-condition medical doctors not inclined to superlatives.

“This is genuinely a sport changer,” stated Dr. Daniel Griffin, an skilled on infectious health conditions and immunology at Columbia College. “This is up there with vaccines. It truly is not a substitute for vaccines we continue to want to get people vaccinated. But, boy, this is just a further great instrument to have.”

The new regimens, which involve 30 or 40 supplements to be taken around five days, have been proven to radically reduce hospitalizations and prevent fatalities in grownups with mild to moderate covid who are at chance for severe illness because of age or fundamental conditions. But specialists say the good results of the treatment plans would hinge on a single unsure component: regardless of whether large-danger patients contaminated with covid will be capable to get analyzed — and then addressed — quickly ample to make a difference.

“Early, obtainable tests and entry to the benefits in a time frame that makes it possible for us to make a selection is truly heading to be critical to these medicines,” reported Dr. Erica Johnson, who chairs the Infectious Illness Board of the American Board of Interior Drugs. “It puts the onus on our general public wellbeing system to make these readily available.”

In medical trials, molnupiravir, the antiviral drug created by Merck & Co. and Ridgeback Biotherapeutics, was offered to non-hospitalized, unvaccinated, high-risk grownup people inside five days of their 1st covid indicators. Pfizer’s item, Paxlovid, was tested in equivalent individuals as early as 3 days — just 72 hrs — just after symptoms emerged.

The FDA will soon decide on Merck's Covid-19 antiviral pill. It shows promise, but there are also concerns
Effects from the Merck demo, produced last thirty day period, confirmed the drug lowered the chance of hospitalizations by about 50% and prevented fatalities fully. It will be regarded as by an advisory panel to the federal Meals and Drug Administration on Nov. 30. Pfizer officials, who asked for Food and drug administration crisis authorization for their drug on Nov. 16, mentioned Paxlovid cut the danger of hospitalizations and fatalities by 89%. Each medicines function by hampering the way the covid virus reproduces, although they do so at distinctive factors in the procedure.
But individuals promising final results think the medications can be administered in the slim window of time utilized in the trials, a proven problem when receiving antiviral treatments to real sufferers. Very similar drugs can prevent dire results from influenza if presented early, but analysis shows that only about 40% of superior-risk clients for the duration of five recent flu seasons sought health care treatment within just a few days of slipping ill.

“That is just not human character,” stated Kelly Wroblewski, director of infectious ailment plans for the Association of Public Overall health Laboratories. “If you have a sniffle, you hold out to see if it gets even worse.”

Even when individuals do request early treatment, obtain to covid testing has been wildly variable because the start out of the

Read More... Read More